Inside the FDA’s New Voucher Program: First 9 Picks Target Diabetes to Vaping
The FDA launched its CNPV pilot program, awarding 9 vouchers to expedite reviews for drugs addressing national priorities like diabetes, vaping, and domestic manufacturing.Summary
The FDA announced the first nine recipients of its new Commissioner’s National Priority Voucher (CNPV) pilot program, designed to accelerate review timelines for drugs addressing critical national health priorities. This initiative modernizes the review process, promising regulatory decisions within 1–2 months of filing a complete application, significantly faster than the traditional 10–12 month timeline. The program aims to spur innovation in areas like unmet medical need, public health crises, domestic drug manufacturing, and affordability. The nine selected products target diverse areas, including Follitropin Alfa + Lutropin Alfa for infertility, Teplizumab for Type 1 Diabetes, Cytisinicline for vaping dependence, DB-OTO gene therapy for deafness, RMC-6236 for pancreatic cancer, and Ketamine and Augmentin XR to incentivize US domestic manufacturing of essential medicines. FDA Commissioner Marty Makary stated the goal is to deliver more cures impacting pressing national priorities.
(Source：HCPLive)
